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Ataxia-telangiectasia (A-T) is a rare autosomal recessive neurodegenerative disorder. It is 
characterized by early-onset, progressive cerebellar ataxia, oculomotor apraxia, choreoath-
etosis, conjunctival telangiectasias, immunodeficiency, and an increased risk of malignan-
cy. Although A-T is known to be the most common cause of progressive cerebellar ataxia 
in childhood, there have been no confirmed cases in Korea. We report the clinical and ge-
netic findings of Korean siblings who presented with limb and truncal ataxia, oculomotor 
apraxia, choreoathetosis, and telangiectasias of the eyes. Sequence analysis of the ataxia-
telangiectasia mutated (ATM) gene revealed a known missense mutation (c.8546G>C; 
p.Arg2849Pro) and a novel intronic variant of intron 17 (c.2639-19_2639-7del13). Reverse-
transcription PCR and sequencing analysis revealed that the c.2639-19_2639-7del13 vari-
ant causes a splicing aberration that potentiates skipping exon 18. Because A-T is quite 
rare in Korea, the diagnosis of A-T in Korean patients can be delayed. We recommend 
that a diagnosis of A-T should be suspected in Korean patients exhibiting the clinical fea-
tures of A-T.
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INTRODUCTION
Ataxia-telangiectasia (A-T; MIM #208900) is an autosomal reces-
sive, multi-system disorder with onset during childhood that 
is characterized by progressive cerebellar ataxia, oculomotor 
apraxia, oculocutaneous telangiectasias, choreoathetosis, im-
munodeficiency, frequent infections, elevated alpha-fetoprotein 
(AFP) levels, chromosomal instability, and an increased risk of 
malignancy, particularly leukemia and lymphoma [1]. A-T cells 
are hypersensitive to ionizing radiation and radiomimetic chemi-
cals because of defects in cell cycle checkpoints that are nor-
mally activated by DNA damage [2].
 The ataxia-telangiectasia mutated (ATM) gene-localized on 
chromosome 11 at position q22-23−has been identified by posi-
tional cloning [3]. The gene encodes a large protein, ATM, with 
a molecular mass of approximately 350 kDa. The protein en-
coded by the ATM gene belongs to the phosphatidylinositol 
(PI)3/PI4 kinase family, which is a cell cycle checkpoint kinase. 
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The protein functions as a regulator of a wide variety of down-
stream proteins, including tumor suppressor proteins p53 and 
BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 
and RAD9, and the DNA repair protein NBS1 [4]. Most ATM 
mutations are private mutations and, to date, no mutational hot-
spots have been identified in the ATM gene.
 Although A-T is known in most countries to be the most com-
mon cause of progressive cerebellar ataxia in childhood, there 
have been no confirmed cases in Korea. In this report, we pres-
ent the clinical features of a pair of Korean siblings with A-T that 
were found to be heterozygous for two ATM gene mutations.
CASE REPORT
1. Clinical findings
An 8-yr-old boy and his 6-yr-old sister presented to the neurol-
ogy outpatient clinic with a chief complaint of progressive ataxia. 
The patients displayed progressive limb and truncal ataxia, as 
well as involuntary movements of the extremities. There was no 
history of perinatal complications, cognitive dysfunction, or sei-
zures. The proband had developed recurrent respiratory infec-
tions. The parents were healthy, non-consanguineous ethnic 
Koreans. The proband was the first child in his family, and no 
family history other than the two patients was known.
 The proband first presented to the pediatrics clinic four years 
prior to the neurology visit. A blood test at the initial visit showed 
mild anemia (11.6 g/dL), thrombocytosis (441×109/L), and an 
elevated phosphate level (5.2 mg/dL). Serum levels of lactate, 
pyruvate, and cholesterol were within normal limits. There were 
no detectable abnormalities in the urine, and the levels of se-
rum amino acids and urine organic amino acids were normal. 
Left undiagnosed for three years, the patient had only received 
conservative care and rehabilitation.
 When both siblings presented to the department of neurology, 
the proband exhibited more severe symptoms. A neurological 
examination revealed the presence of limb and truncal ataxia, 
oculomotor apraxia with gaze-evoked nystagmus, and choreo-
athetosis of the bilateral extremities. There was no cranial nerve 
dysfunction, motor weakness, or sensory dysfunction. Deep ten-
don reflexes were decreased. Ophthalmologic evaluation did not 
reveal telangiectasia in either of the children. The AFP level was 
increased (119.68 IU/mL) in the proband’s serum. No chromo-
somal abnormalities were found. The number of CAG repeats 
was not increased in the genes for spinocerebellar ataxia type 1, 
2, 3, 6, 7, 8, or 17. Cerebellar atrophy on brain magnetic reso-
nance imaging (MRI) images taken two years prior to the visit 
was more prominent than that in the initial image taken 4 yr 
ago.
2. Molecular genetic analysis
After obtaining informed consent from the parents, the genomic 
DNA was isolated from peripheral blood leukocytes of the pro-
band and his siblings by using a Wizard genomic DNA purifica-
tion kit (Promega, Madison, WI, USA). All the coding exons and 
flanking intronic regions of the ATM gene were amplified using 
primer sets designed by the authors (sequences available upon 
request). PCR was performed using a thermal cycler (Model 
9700; Applied Biosystems, Foster City, CA, USA). Direct se-
quencing was performed using an ABI Prism 3130xl Genetic 
Analyzer (Applied Biosystems) with a BigDye Terminator Cycle 
Sequencing-Ready Reaction Kit (Applied Biosystems).
 RNA was extracted to perform reverse-transcription PCR (RT-
PCR). cDNA was generated using an RNA PCR kit (Applied 
Biosystems). RT-PCR–based sequencing was performed using 
a set of primers (RT-F, 5’-CCAATTCTTCACAGTAATTTTCCTC-3’; 
RT-R, 5’-CGATACAAAGAACACACATTGGA-3’). The PCR product 
obtained was subjected to direct sequencing as described 
above.
 The cDNA nucleotide sequences of the gene examined were 
numbered according to the GenBank accession number 
NM_000051.3 for ATM. The mutation nomenclature used here 
follows the recommendations of the Human Genome Variation 
Society (http://www.hgvs.org/mutnomen/).
3. Molecular genetic findings
In the proband, a previously reported heterozygous mutation at 
position 8,546 (c.8546G>C; p.Arg2849Pro) [5] and a 13-base 
deletion in intron 17 (c.2639-19_2639-7del13) were identified 
(Fig. 1). RT-PCR analysis revealed that the intronic variant re-
sulted in a marked increase of an aberrant transcript missing 
exon 18 (954 bp) that was only faintly observed in normal con-
trols (Fig. 2). These two variants were also present in the af-
fected sister, but they were absent in the proband’s healthy 
brother. In addition, the c.2639-19_2639-7del13 variant was not 
found in 100 control chromosomes.
DISCUSSION
A-T is a rare neurodegenerative disease, but in most countries, 
it is the most frequent autosomal recessive cause of progressive 
cerebellar ataxia in childhood [6]. A-T has a wide ethnic and 
geographic distribution. The prevalence of A-T has been re-
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ported to range from 1 in 40,000 to 1 in 300,000 live births, de-
pending on the geographic or ethnic region [7, 8]. Moreover, the 
type and frequency of specific mutations in different localities 
can vary widely, with some regions having a specific founder 
mutation [9, 10]. In Asia, a nationwide survey was conducted to 
identify A-T patients in Japan, and the first reports of Chinese 
patients with ATM mutations surfaced in 2006 [11, 12]. The 
prevalence of A-T in the Korean population appears to be ex-
tremely low, with only a few cases reported thus far [13, 14]. 
The precise incidence, clinical characteristics, and genetics of 
A-T in the Korean population are unknown because of a lack of 
epidemiological surveys.
 The patients in this study showed signs and symptoms of A-T, 
such as cerebellar ataxia, oculomotor apraxia, and elevated AFP 
levels. Contrary to the commonly associated characteristics, 
these patients’ eyes and skin were without telangiectasias. 
Therefore, variant A-T−defined as the absence or presence later 
in life of some of the hallmarks of classic A-T−could not be 
ruled out, although telangiectasia may appear several years af-
ter the onset of neurologic symptoms [15-17].
 On mutation analysis, our patients were shown to have two 
heterozygous variants. The c.8546G>C (p.Arg2849Pro) muta-
tion, located in exon 58, is a known mutation that was first de-
scribed by Sandoval et al. [5]. This mutation was reported to re-
side within the kinase domain and to affect residues that are 
highly conserved in the ATM-homologous proteins of different 
species. In addition, a novel c.2639-19_2639-7del13 variant in 
intron 17 was identified. RT-PCR analysis of the ATM mRNA 
showed that this variant resulted in aberrant skipping of exon 
18. Although a small amount of alternatively spliced transcript 
without exon 18 was detected in normal controls, the amount of 
aberrant transcript markedly increased with the variant.
 The clinical diagnosis of A-T is difficult when typical manifes-
tations such as telangiectasia are absent. In addition, A-T is 
quite rare in Korea, which could lead to a delay in the diagnosis. 
Detecting ATM mutations in A-T patients could be useful diag-
nostically, especially in the early stages or in variant A-T. Al-
though curative treatment strategies are not available for A-T, 
early diagnosis is of particular importance, given the increased 
risk of malignancy. The early recognition of A-T is a prerequisite 
to provide a correct prognosis and appropriate rehabilitation and 
support, including the avoidance of diagnostic X-ray procedures 
because of A-T–related radiosensitivity [16, 17].
 Unfortunately, we could not confirm the compound heterozy-
gosity of the 2 variants identified in this study, because both 
parents of the patients refused genetic testing for themselves, 
and the younger sibling of the patients did not have either of the 
Fig. 2. RT-PCR sequencing of the ATM gene. (A) Electrophoresis of 
RT-PCR products using the primer pair described in the Case Re-
port demonstrates an additional band (954 bp), as well as the ex-
pected band (1,154 bp), in the proband. The density of the aber-
rant band is much stronger in the proband than in controls. (B) Se-
quencing of the RT-PCR products demonstrated the aberrant skip-
ping of exon 18.
Abbreviations: RT-PCR, reverse-transcription polymerase chain reaction; 
ATM, ataxia-telangiectasia mutated.
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Fig. 1. (A) Pedigree of the family with A-T and (B-C) genomic DNA 
sequence analysis of the ATM gene in the proband and his siblings. 
(B) The patient was identified as being compound heterozygous for 
mutations of the ATM gene. The solid arrow indicates overlapping 
peaks at nucleotide position 8,546 because of a heterozygous G>C 
transition (c.8546G>C, p.Arg2849Pro). (C) The open arrow indi-
cates the presence of successive double peaks at nucleotide posi-
tion 2,639-19, suggesting the deletion of 13 base pairs (c.2639-
19_2639-7delGAGTGCTTTTTAT).
Abbreviations: A-T, ataxia-telangiectasia; ATM, ataxia-telangiectasia mutated.
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two variants. Nevertheless, the presence of a novel splicing vari-
ant, as well as a known mutation in the two patients with A-T, 
highly suggests that the two variants might be causative muta-
tions in the siblings.
 In conclusion, this study reports Korean siblings with A-T car-
rying a known mutation and a novel splicing variant of the ATM 
gene. It should be noted that the diagnosis of A-T should be 
suspected, even in Korea, in patients exhibiting the clinical fea-
tures of A-T. This study highlights the need for additional re-
search on a large set of patients in this regional population. It is 
expected that such studies will help us better understand this 
serious disorder and develop appropriate therapeutic strategies.
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